Expression of VOPP1 in hepatocellular carcinoma and its relationship with prognosis

doi:10.3877/cma.j.issn.2095-3232.2024026

Abstract

Abstract:

Objective

To investigate the expression of vesicular over-expressed in cancer prosurvival protein 1 （VOPP1） in hepatocellular carcinoma （HCC） and its relationship with clinical prognosis of HCC patients.

Methods

Clinicopathological data of 90 HCC patients who underwent radical resection in the Third Affiliated Hospital of Sun Yat-sen University from February 2008 to August 2015 were retrospectively analyzed. The informed consents of all patients were obtained and the local ethical committee approval was received. Among them，81 patients were male and 9 female，aged 27-74 years，with a median age of 53 years. 11 cases were classified as TNM stage Ⅰ，29 cases of TNM stage Ⅱ，26 cases of TNM stage Ⅲ and 2 cases of TNM stage Ⅳ. The expression level of VOPP1 in HCC and adjacent tissues was determined by immunohistochemical staining，and the relationship between VOPP1 expression and clinicopathological parameters was analyzed. In addition，the expression level of VOPP1 mRNA in the cancer and adjacent tissues of 10 HCC patients was detected by qRT-PCR. Survival analysis was conducted by Kaplan-Meier method and Log-rank test. The independent risk factors of clinical prognosis were assessed by Cox regression model.

Results

qRT-PCR showed that the average relative expression of VOPP1 mRNA in HCC tissues was （4.91±1.98）×10^-3，significantly higher than （0.39±0.12）×10^-3 in paired adjacent tissues （t=2.284， P＜0.05）. Immunohistochemical staining showed that the positive expression rate of VOPP1 in HCC was 52%（47/90），significantly higher than 28%（25/90） in adjacent tissues （χ²=11.204， P＜0.05）.The high expression of VOPP1 in HCC tissues was correlated with histological grade （χ²=9.373， P＜0.05）.Survival analysis showed that the median recurrence-free survival （RFS） of HCC patients with high and low expression of VOPP1 after radical resection was 17 and 50 months，respectively. The RFS of patients with high expression of VOPP1 was significantly lower than that of their counterparts with low expression of VOPP1 （χ²=7.769， P＜0.05）. Cox regression analysis showed that T3 stage （HR=3.649，95%CI: 1.278-10.420），T4 stage （HR=6.157，95%CI: 1.297-29.235） and high expression of VOPP1 protein （HR=1.866，95%CI: 1.069-3.258） were the independent risk factors of postoperative RFS （P＜0.05）.

Conclusions

VOPP1 is highly expressed in HCC tissues. The expression level of VOPP1 is negatively correlated with clinical prognosis. VOPP1 is an independent risk factor of clinical prognosis of HCC，which can be utilized as a new and valuable prognostic factor.

Key words: Carcinoma，hepatocellular, Prognosis, VOPP1, Tumor markers

Xiaopeng Chen, Jiani Wang, Qinghai Lian, Jiumei Yang. Expression of VOPP1 in hepatocellular carcinoma and its relationship with prognosis[J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(06): 876-882.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhgzwkssxdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3232.2024026

https://zhgzwkssxdzzz.cma-cmc.com.cn/EN/Y2024/V13/I06/876

Figures/Tables 5

References 23

［1］	Sung H，Ferlay J，Siegel RL，et al. Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］. CA Cancer J Clin，2021，71（3）: 209-249.
［2］	Siegel R，Miller K，Wagle NS，et al. Cancer statistics，2023［J］. CA A Cancer J Clin，2023，73:17-48.
［3］	Wen N，Cai Y，Li F，et al. The clinical management of hepatocellular carcinoma worldwide: a concise review and comparison of current guidelines: 2022 update［J］. Biosci Trends，2022，16（1）:20-30.
［4］	Xia C，Dong X，Li H，et al. Cancer statistics in China and United States，2022: profiles，trends，and determinants［J］. Chin Med J，2022，135（5）:584-590.
［5］	Liu J，Zhao SY，Jiang Q，et al. Long noncoding RNA MYLK-AS1 promotes growth and invasion of hepatocellular carcinoma through the EGFR/HER2-ERK1/2 signaling pathway［J］. Int J Biol Sci，2020，16（11）:1989-2000.
［6］	Ganesan P，Kulik LM. Hepatocellular carcinoma: new developments［J］. Clin Liver Dis，2023，27（1）:85-102.
［7］	吴虹霖，牛翔科，熊燕，等. 肝细胞肝癌的免疫治疗现状及研究进展［J］. 中国免疫学杂志，2021，37（22）:2771-2778.
［8］	郑荣寿，张思维，孙可欣，等. 2016年中国恶性肿瘤流行情况分析［J］. 中华肿瘤杂志，2023，45（3）:212-220.
［9］	Sugawara Y，Hibi T. Surgical treatment of hepatocellular carcinoma［J］. Biosci Trends，2021，15（3）:138-141.
［10］	中华人民共和国国家卫生健康委员会. 原发性肝癌诊疗指南（2022年版）［J/OL］. 肿瘤综合治疗电子杂志，2022，8（2）:16-53.
［11］	Pang BY，Leng Y，Wang X，et al. A meta-analysis and of clinical values of 11 blood biomarkers，such as AFP，DCP，and GP73 for diagnosis of hepatocellular carcinoma［J］. Ann Med，2023，55（1）:42-61.
［12］	Park S，James CD. ECop （EGFR-coamplified and overexpressed protein），a novel protein，regulates NF-kappaB transcriptional activity and associated apoptotic response in an IkappaBalphadependent manner［J］. Oncogene，2005，24（15）:2495-2502.
［13］	Baras AS，Solomon A，Davidson R，et al. Loss of VOPP1 overexpression in squamous carcinoma cells induces apoptosis through oxidative cellular injury［J］. Lab Invest，2011，91（8）:1170-1180.
［14］	Gao C，Pang M，Zhou Z，et al. Epidermal growth factor receptorcoamplified and overexpressed protein （VOPP1） is a putative oncogene in gastric cancer［J］. Clin Exp Med，2015，15（4）:469-475.
［15］	Mattern J，Koomägi R，Volm M. Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumour cell proliferation in human epidermoid lung carcinoma［J］. Br J Cancer，1996，73（7）:931-934.
［16］	Masuda H，Zhang D，Bartholomeusz C，et al. Role of epidermal growth factor receptor in breast cancer［J］. Breast Cancer Res Treat，2012，136（2）:331-345.
［17］	Staudt C，Puissant E，Boonen M. Subcellular trafficking of mammalian lysosomal proteins: an extended view［J］. Int J Mol Sci，2016，18（1）:47.
［18］	Li YJ，Zhang W，Xia H，et al. MiR-218 suppresses epithelial-tomesenchymal transition by targeting Robo1 and Ecop in lung adenocarcinoma cells［J］. Future Oncol，2017，13（28）:2571-2582.
［19］	Karin M，Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-［kappa］B activity［J］. Annu Rev Immunol，2000，18:621-663.
［20］	Li JM，Zhang H，Zuo YJ. MicroRNA-218 alleviates sepsis inflammation by negatively regulating VOPP1 via JAK/STAT pathway［J］. Eur Rev Med Pharmacol Sci，2018，22（17）:5620-5626.
［21］	Xia H，Yan Y，Hu M，et al. MiR-218 sensitizes glioma cells to apoptosis and inhibits tumorigenicity by regulating ECOP-mediated suppression of NF-κB activity［J］. Neuro Oncol，2013，15（4）:413-422.
［22］	Sliwkowski MX，Mellman I. Antibody therapeutics in cancer［J］.Science，2013，341（6151）:1192-1198.
［23］	Bonin F，Taouis K，Azorin P，et al. VOPP1 promotes breast tumorigenesis by interacting with the tumor suppressor WWOX［J］.BMC Biol，2018，16（1）:109.

指标	例数	VOPP1低表达组	VOPP1高表达组	χ ²值	P值
男性	81	40	41	0.836	0.360
年龄≥60岁	24	10	14	0.490	0.484
HBV感染	85	39	46	2.203	0.138
肿瘤直径≥5cm	39	16	23	1.258	0.262
组织学分级				9.373	0.007
Ⅰ级	3	2	1
Ⅱ级	54	26	28
Ⅲ级	33	15	18
AJCC分期				-	0.463
Ⅰ期	11	7	4
Ⅱ期	29	14	15
Ⅲ期	48	22	26
Ⅳ期	2	0	2

指标	例数	VOPP1低表达组	VOPP1高表达组	χ ²值	P值
男性	81	40	41	0.836	0.360
年龄≥60岁	24	10	14	0.490	0.484
HBV感染	85	39	46	2.203	0.138
肿瘤直径≥5cm	39	16	23	1.258	0.262
组织学分级				9.373	0.007
Ⅰ级	3	2	1
Ⅱ级	54	26	28
Ⅲ级	33	15	18
AJCC分期				-	0.463
Ⅰ期	11	7	4
Ⅱ期	29	14	15
Ⅲ期	48	22	26
Ⅳ期	2	0	2

参数	单因素分析			多因素分析
参数	HR	95%CI	P值	HR	95%CI	P值
HBV感染	2.797	1.102～7.096	0.030
肿瘤直径≥5cm	2.065	1.219～3.500	0.007
AJCC分期			0.001
Ⅰ期	参考
Ⅱ期	1.520	0.494～4.673	0.465
Ⅲ期	4.098	1.445～11.617	0.008
Ⅳ期	14.278	2.505～81.377	0.003
VOPP1高表达	2.104	1.225～3.613	0.007	1.866	1.069～3.258	0.028
T分期			0.001			0.003
1期	参考			参考
2期	1.519	0.494～4.672	0.465	1.370	0.444～4.232	0.584
3期	4.075	1.436～11.567	0.008	3.649	1.278～10.420	0.016
4期	8.727	1.892～40.251	0.005	6.157	1.297～29.235	0.022

参数	单因素分析			多因素分析
参数	HR	95%CI	P值	HR	95%CI	P值
HBV感染	2.797	1.102～7.096	0.030
肿瘤直径≥5cm	2.065	1.219～3.500	0.007
AJCC分期			0.001
Ⅰ期	参考
Ⅱ期	1.520	0.494～4.673	0.465
Ⅲ期	4.098	1.445～11.617	0.008
Ⅳ期	14.278	2.505～81.377	0.003
VOPP1高表达	2.104	1.225～3.613	0.007	1.866	1.069～3.258	0.028
T分期			0.001			0.003
1期	参考			参考
2期	1.519	0.494～4.672	0.465	1.370	0.444～4.232	0.584
3期	4.075	1.436～11.567	0.008	3.649	1.278～10.420	0.016
4期	8.727	1.892～40.251	0.005	6.157	1.297～29.235	0.022

[1]	Jie Xu, Yajun Li, Junwei Han. Comparison of the efficacy of radical laparoscopic total gastrectomy in the treatment of overweight gastric cancer with two approaches [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2025, 19(01): 19-22.
[2]	Jiehong Gao, Pingping Li, Jing Qi, Yinhai Dai. Study on the relationship between the expression of ETFA gene and clinicopathological parameters and prognosis in breast cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2025, 19(01): 64-67.
[3]	Daiqin Li, Peijie Liu. Value of dynamic enhanced magnetic resonance imaging in evaluating the efficacy and prognosis of middle and advanced low rectal cancer after concurrent chemoradiotherapy [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2025, 19(01): 100-103.
[4]	Yu Gong, Yuan Liao, Mei Shang. Influencing factors and prediction model for recurrence of hepatocellular carcinoma after TACE [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(06): 818-824.
[5]	Yifan Li, Diwen Zhu, Weixin Ren, Yingjun Bao, Junpeng Gu, Haixiao Zhang, Gengfei Cao, Weizheng Ji. Role of serum GP73 level in the evaluation of TACE efficacy for primary liver cancer [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(06): 825-830.
[6]	Minsi Liu, Rong Li, Mei Li. Diagnostic value of GGT-Plt ratio-based model for HBV-related hepatocellular carcinoma [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(06): 831-835.
[7]	Xiaoling Guan, Wenying Zhou, Hongping Chen. Predictive value of PTAAR for short-term prognosis of patients with hepatitis B virus-related acuteon-chronic liver failure [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(06): 841-845.
[8]	Zhendong Jiao, Peng Hui, Shangbo Jin. Application of three-dimensional visualization combined with ICG imaging technology in laparoscopic hepatectomy for recurrent hepatocellular carcinoma [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(06): 859-864.
[9]	Runjin Zhang, Pan Yang, Yansi Lin, Zunlong Liu, Jianping Liu, Xiaoyan Jin. Epstein-Barr virus-associated cholangiocarcinoma complicated with multiple metastases: a case report and Chinese literature review [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(06): 865-869.
[10]	Yuhan Yuan, Shengli Yang. Research progress in proteomic analysis of body fluids and tissues in early molecular diagnosis of liver cancer [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(06): 883-888.
[11]	Jing Wu, Hao Wen. New progress in liver function evaluation before hepatectomy [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(06): 889-893.
[12]	Hongxia Yan, Xiaojuan Wang, Yixun Zhang. The effect of type 2 diabetes on tumor markers， clinicopathology and prognosis in patients with colorectal cancer [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2024, 13(06): 483-487.
[13]	Yu Liu, Shaobin Duan, Zhixiang Ding, Zhitao Shi. Expression of miR-34a-5p in colon cancer patients and its correlation with clinical characteristics and prognosis [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2024, 14(06): 485-490.
[14]	Qianqian Chen, Chen Yuan, Ji Liu, Tingting Yin. Effects of multi-slice spiral CT parameters，carcinoembryonic antigen，mismatch repair gene，and pathological indicators on prognosis of colorectal cancer [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2024, 14(06): 507-511.
[15]	Mingfen Zeng, Yan Wang. Study on the correlation between CT and color Doppler ultrasound diagnostic parameters and the condition and prognosis of patients with acute pancreatitis complicated with fatty liver [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2024, 14(06): 531-535.

Please choose a citation manager

Content to export